{
    "info": {
        "nct_id": "NCT06453460",
        "official_title": "Prospective Evaluation of Efficacy of CMV-specific T Cell Immunity (CMV-TCIP) Directed Letermovir Prophylaxis After Allogeneic Hematopoietic Cell Transplantation",
        "inclusion_criteria": "* ≥ 18 years of age on the day of signing informed consent.\n* Karnofsky performance >70%\n* Have documented seropositivity for CMV (either donor or recipient CMV IgG seropositivity) before AHCT.\n* Eligible for AHCT from an HLA-matched related, matched unrelated, mismatched unrelated or haploidentical donor using either bone marrow or peripheral blood stem cells.\n* Have undetectable CMV DNA from a plasma sample collected within 5 days prior to enrollment.\n* Be within 28 days post-HSCT at the time of enrollment.\n* Be able to comply with medical recommendations or follow-up.\n* Has adequate organ functions determined by\n\n  1. Serum creatinine clearance ≥50 ml/min (calculated with Cockroft-Gault formula).\n  2. Bilirubin ≤1.5 mg/dl except for Gilbert's disease.\n  3. ALT or AST ≤200 IU/ml for adults.\n  4. Conjugated (direct) bilirubin < 2x upper limit of normal.\n  5. Left ventricular ejection fraction ≥40%.\n  6. Diffusing capacity for carbon monoxide (DLCO) ≥ 50% predicted corrected for hemoglobin.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Has a history of CMV end-organ disease or CS-CMVi within 6 months prior to enrollment.\n* Received within 7 days prior to screening or plans to receive during the study any of the following:\n\n  1. Ganciclovir\n  2. Valganciclovir\n  3. Foscarnet\n  4. Acyclovir (> 3200 mg PO per day or > 25 mg/kg IV per day)\n  5. Valacyclovir (> 3000 mg/day)\n  6. Famciclovir (> 1500 mg/day)\n* Received within 30 days prior to screening or plans to receive during the study any of the following drugs: cidofovir, CMV hyper-immune globulin, any investigational CMV antiviral agent/biologic therapy.\n* Has suspected or known hypersensitivity to active or inactive ingredients of letermovir formulations.\n* Has an uncontrolled infection on the day of randomization.\n* Requires mechanical ventilation or is hemodynamically unstable at the time of randomization.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* ≥ 18 years of age on the day of signing informed consent.",
            "criterions": [
                {
                    "exact_snippets": "≥ 18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eligible for AHCT from an HLA-matched related, matched unrelated, mismatched unrelated or haploidentical donor using either bone marrow or peripheral blood stem cells.",
            "criterions": [
                {
                    "exact_snippets": "Eligible for AHCT",
                    "criterion": "eligibility for AHCT",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "from an HLA-matched related, matched unrelated, mismatched unrelated or haploidentical donor",
                    "criterion": "donor HLA compatibility",
                    "requirements": [
                        {
                            "requirement_type": "HLA match type",
                            "expected_value": [
                                "HLA-matched related",
                                "matched unrelated",
                                "mismatched unrelated",
                                "haploidentical"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "using either bone marrow or peripheral blood stem cells",
                    "criterion": "stem cell source",
                    "requirements": [
                        {
                            "requirement_type": "source type",
                            "expected_value": [
                                "bone marrow",
                                "peripheral blood stem cells"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Karnofsky performance >70%",
            "criterions": [
                {
                    "exact_snippets": "Karnofsky performance >70%",
                    "criterion": "Karnofsky performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">",
                                "value": 70,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have documented seropositivity for CMV (either donor or recipient CMV IgG seropositivity) before AHCT.",
            "criterions": [
                {
                    "exact_snippets": "documented seropositivity for CMV (either donor or recipient CMV IgG seropositivity) before AHCT",
                    "criterion": "CMV seropositivity",
                    "requirements": [
                        {
                            "requirement_type": "seropositivity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "source",
                            "expected_value": [
                                "donor",
                                "recipient"
                            ]
                        },
                        {
                            "requirement_type": "test",
                            "expected_value": "CMV IgG"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "before AHCT"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Be within 28 days post-HSCT at the time of enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Be within 28 days post-HSCT at the time of enrollment.",
                    "criterion": "time since HSCT",
                    "requirements": [
                        {
                            "requirement_type": "time since HSCT",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 28,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Be able to comply with medical recommendations or follow-up.",
            "criterions": [
                {
                    "exact_snippets": "Be able to comply with medical recommendations or follow-up.",
                    "criterion": "ability to comply with medical recommendations or follow-up",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has adequate organ functions determined by",
            "criterions": [
                {
                    "exact_snippets": "Has adequate organ functions",
                    "criterion": "organ functions",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Serum creatinine clearance ≥50 ml/min (calculated with Cockroft-Gault formula).",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine clearance ≥50 ml/min (calculated with Cockroft-Gault formula)",
                    "criterion": "serum creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "ml/min"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockroft-Gault formula"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Bilirubin ≤1.5 mg/dl except for Gilbert's disease.",
            "criterions": [
                {
                    "exact_snippets": "Bilirubin ≤1.5 mg/dl except for Gilbert's disease.",
                    "criterion": "bilirubin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "mg/dl"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "Gilbert's disease"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. ALT or AST ≤200 IU/ml for adults.",
            "criterions": [
                {
                    "exact_snippets": "ALT or AST ≤200 IU/ml for adults",
                    "criterion": "ALT level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 200,
                                "unit": "IU/ml"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "ALT or AST ≤200 IU/ml for adults",
                    "criterion": "AST level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 200,
                                "unit": "IU/ml"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Conjugated (direct) bilirubin < 2x upper limit of normal.",
            "criterions": [
                {
                    "exact_snippets": "Conjugated (direct) bilirubin < 2x upper limit of normal",
                    "criterion": "conjugated (direct) bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "x upper limit of normal"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Left ventricular ejection fraction ≥40%.",
            "criterions": [
                {
                    "exact_snippets": "Left ventricular ejection fraction ≥40%",
                    "criterion": "left ventricular ejection fraction",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Diffusing capacity for carbon monoxide (DLCO) ≥ 50% predicted corrected for hemoglobin.",
            "criterions": [
                {
                    "exact_snippets": "Diffusing capacity for carbon monoxide (DLCO) ≥ 50% predicted corrected for hemoglobin.",
                    "criterion": "diffusing capacity for carbon monoxide (DLCO)",
                    "requirements": [
                        {
                            "requirement_type": "percentage of predicted (corrected for hemoglobin)",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "% of predicted"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Have undetectable CMV DNA from a plasma sample collected within 5 days prior to enrollment.",
            "criterions": [
                {
                    "exact_snippets": "undetectable CMV DNA from a plasma sample collected within 5 days prior to enrollment",
                    "criterion": "CMV DNA in plasma",
                    "requirements": [
                        {
                            "requirement_type": "detectability",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "sample collection window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "days prior to enrollment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "3. Foscarnet",
            "criterions": [
                {
                    "exact_snippets": "Foscarnet",
                    "criterion": "Foscarnet use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Requires mechanical ventilation or is hemodynamically unstable at the time of randomization.",
            "criterions": [
                {
                    "exact_snippets": "Requires mechanical ventilation",
                    "criterion": "mechanical ventilation",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hemodynamically unstable at the time of randomization",
                    "criterion": "hemodynamic stability",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "unstable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has an uncontrolled infection on the day of randomization.",
            "criterions": [
                {
                    "exact_snippets": "Has an uncontrolled infection on the day of randomization",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "presence on day of randomization",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a history of CMV end-organ disease or CS-CMVi within 6 months prior to enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Has a history of CMV end-organ disease",
                    "criterion": "CMV end-organ disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "CS-CMVi within 6 months prior to enrollment",
                    "criterion": "CS-CMVi",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to enrollment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has suspected or known hypersensitivity to active or inactive ingredients of letermovir formulations.",
            "criterions": [
                {
                    "exact_snippets": "Has suspected or known hypersensitivity to active or inactive ingredients of letermovir formulations.",
                    "criterion": "hypersensitivity to letermovir formulations",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Valacyclovir (> 3000 mg/day)",
            "criterions": [
                {
                    "exact_snippets": "Valacyclovir (> 3000 mg/day)",
                    "criterion": "Valacyclovir dosage",
                    "requirements": [
                        {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "operator": ">",
                                "value": 3000,
                                "unit": "mg/day"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Valganciclovir",
            "criterions": [
                {
                    "exact_snippets": "Valganciclovir",
                    "criterion": "valganciclovir use",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Famciclovir (> 1500 mg/day)",
            "criterions": [
                {
                    "exact_snippets": "Famciclovir (> 1500 mg/day)",
                    "criterion": "Famciclovir dosage",
                    "requirements": [
                        {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "operator": ">",
                                "value": 1500,
                                "unit": "mg/day"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Acyclovir (> 3200 mg PO per day or > 25 mg/kg IV per day)",
            "criterions": [
                {
                    "exact_snippets": "Acyclovir (> 3200 mg PO per day or > 25 mg/kg IV per day)",
                    "criterion": "acyclovir dosage",
                    "requirements": [
                        {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 3200,
                                        "unit": "mg PO per day"
                                    },
                                    {
                                        "operator": ">",
                                        "value": 25,
                                        "unit": "mg/kg IV per day"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received within 7 days prior to screening or plans to receive during the study any of the following:",
            "criterions": [
                {
                    "exact_snippets": "Received within 7 days prior to screening",
                    "criterion": "receipt of any of the following",
                    "requirements": [
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to screening"
                            }
                        },
                        {
                            "requirement_type": "receipt",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "plans to receive during the study any of the following",
                    "criterion": "planned receipt of any of the following",
                    "requirements": [
                        {
                            "requirement_type": "planned receipt during study",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received within 30 days prior to screening or plans to receive during the study any of the following drugs: cidofovir, CMV hyper-immune globulin, any investigational CMV antiviral agent/biologic therapy.",
            "criterions": [
                {
                    "exact_snippets": "Received within 30 days prior to screening ... any of the following drugs: cidofovir, CMV hyper-immune globulin, any investigational CMV antiviral agent/biologic therapy.",
                    "criterion": "receipt of specified drugs within 30 days prior to screening",
                    "requirements": [
                        {
                            "requirement_type": "receipt",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days prior to screening"
                            }
                        },
                        {
                            "requirement_type": "drug",
                            "expected_value": [
                                "cidofovir",
                                "CMV hyper-immune globulin",
                                "any investigational CMV antiviral agent/biologic therapy"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "plans to receive during the study any of the following drugs: cidofovir, CMV hyper-immune globulin, any investigational CMV antiviral agent/biologic therapy.",
                    "criterion": "planned receipt of specified drugs during the study",
                    "requirements": [
                        {
                            "requirement_type": "planned receipt",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": "during the study"
                        },
                        {
                            "requirement_type": "drug",
                            "expected_value": [
                                "cidofovir",
                                "CMV hyper-immune globulin",
                                "any investigational CMV antiviral agent/biologic therapy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Ganciclovir",
            "criterions": [
                {
                    "exact_snippets": "Ganciclovir",
                    "criterion": "Ganciclovir",
                    "requirements": [
                        {
                            "requirement_type": "exposure or use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}